Bioethics, Ltd. Logo

Bioethics, Ltd.

BOTH

(1.5)
Stock Price

1,09 USD

-1202.68% ROA

15.31% ROE

-19.03x PER

Market Cap.

2.327.140,00 USD

-57.72% DER

0% Yield

0% NPM

Bioethics, Ltd. Stock Analysis

Bioethics, Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bioethics, Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-0.33x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (-59%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

ROE in an average range (13.48%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROA

The stock's ROA (-19735.73%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Bioethics, Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bioethics, Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Bioethics, Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bioethics, Ltd. Revenue
Year Revenue Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bioethics, Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bioethics, Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 11.823 100%
2009 21.941 46.11%
2010 15.370 -42.75%
2011 22.474 31.61%
2012 22 -102054.55%
2013 17.941 99.88%
2014 18.568 3.38%
2015 46.546 60.11%
2016 50.244 7.36%
2017 45.720 -9.9%
2018 47.981 4.71%
2019 70.033 31.49%
2020 75.141 6.8%
2021 59.367 -26.57%
2022 47.303 -25.5%
2023 40.016 -18.21%
2023 44.442 9.96%
2024 91.916 51.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bioethics, Ltd. EBITDA
Year EBITDA Growth
1997 0
1998 -5.335 100%
1999 -5.531 3.54%
2000 -6.081 9.04%
2001 -6.758 10.02%
2002 -5.081 -33.01%
2003 -5.893 13.78%
2004 -5.858 -0.6%
2005 -6.795 13.79%
2006 -15.641 56.56%
2007 -11.021 -41.92%
2008 -11.823 6.78%
2009 -21.941 46.11%
2010 -15.370 -42.75%
2011 -22.474 31.61%
2012 -7 -320957.14%
2013 -4.586 99.85%
2014 -189.623 97.58%
2015 -46.550 -307.35%
2016 -50.180 7.23%
2017 -47.930 -4.69%
2018 -53.700 10.74%
2019 -69.747 23.01%
2020 -74.855 6.82%
2021 -59.141 -26.57%
2022 -47.303 -25.03%
2023 -40.016 -18.21%
2023 -46.707 14.33%
2024 -91.920 49.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bioethics, Ltd. Gross Profit
Year Gross Profit Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 -60 100%
2017 -286 79.02%
2018 -285 -0.35%
2019 -286 0.35%
2020 -286 0%
2021 -226 -26.55%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bioethics, Ltd. Net Profit
Year Net Profit Growth
1997 0
1998 -5.335 100%
1999 -5.531 3.54%
2000 -6.081 9.04%
2001 -6.758 10.02%
2002 -5.081 -33.01%
2003 -5.893 13.78%
2004 -5.858 -0.6%
2005 -6.795 13.79%
2006 -15.641 56.56%
2007 -11.021 -41.92%
2008 -11.823 6.78%
2009 -21.941 46.11%
2010 -16.800 -30.6%
2011 -24.774 32.19%
2012 -26 -95184.62%
2013 -22.527 99.88%
2014 -208.191 89.18%
2015 -95.568 -117.85%
2016 -118.628 19.44%
2017 -64.223 -84.71%
2018 -73.539 12.67%
2019 -133.797 45.04%
2020 -163.241 18.04%
2021 -154.999 -5.32%
2022 -93.203 -66.3%
2023 -89.200 -4.49%
2023 -97.149 8.18%
2024 -143.728 32.41%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bioethics, Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bioethics, Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -4.436
1999 -5.760 22.99%
2000 -6.101 5.59%
2001 -6.224 1.98%
2002 -5.525 -12.65%
2003 -5.893 6.24%
2004 -4.798 -22.82%
2005 -8.555 43.92%
2006 -15.681 45.44%
2007 -9.315 -68.34%
2008 -10.709 13.02%
2009 -16.337 34.45%
2010 -23.794 31.34%
2011 -22.474 -5.87%
2012 -22.484 0.04%
2013 -14.146 -58.94%
2014 -29.863 52.63%
2015 -36.981 19.25%
2016 -43.753 15.48%
2017 -71.176 38.53%
2018 -43.946 -61.96%
2019 -79.251 44.55%
2020 -68.694 -15.37%
2021 -27.483 -149.95%
2022 -25.639 -7.19%
2023 -22.307 -14.94%
2023 -3.690 -504.53%
2024 -33.025 88.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bioethics, Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -4.436
1999 -5.760 22.99%
2000 -6.101 5.59%
2001 -6.224 1.98%
2002 -5.525 -12.65%
2003 -5.893 6.24%
2004 -4.798 -22.82%
2005 -8.555 43.92%
2006 -15.681 45.44%
2007 -9.315 -68.34%
2008 -10.709 13.02%
2009 -16.337 34.45%
2010 -23.794 31.34%
2011 -22.474 -5.87%
2012 -22.484 0.04%
2013 -14.146 -58.94%
2014 -29.863 52.63%
2015 -36.981 19.25%
2016 -42.324 12.62%
2017 -71.176 40.54%
2018 -43.946 -61.96%
2019 -79.251 44.55%
2020 -68.694 -15.37%
2021 -27.483 -149.95%
2022 -25.639 -7.19%
2023 -22.307 -14.94%
2023 -3.690 -504.53%
2024 -33.025 88.83%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bioethics, Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1.429 100%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bioethics, Ltd. Equity
Year Equity Growth
1997 0
1998 34.665 100%
1999 29.134 -18.98%
2000 23.053 -26.38%
2001 16.110 -43.1%
2002 11.029 -46.07%
2003 5.136 -114.74%
2004 -722 811.36%
2005 12.483 105.78%
2006 6.842 -82.45%
2007 10.821 36.77%
2008 -1.002 1179.94%
2009 -5.167 80.61%
2010 -21.967 76.48%
2011 -46.741 53%
2012 -72.786 35.78%
2013 -95.313 23.63%
2014 -5.866 -1524.84%
2015 -1.434 -309.07%
2016 -120.062 98.81%
2017 -184.285 34.85%
2018 -267.824 31.19%
2019 -365.739 26.77%
2020 -478.730 23.6%
2021 -585.913 18.29%
2022 -679.116 13.72%
2023 -751.862 9.68%
2023 -776.265 3.14%
2024 -851.850 8.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bioethics, Ltd. Assets
Year Assets Growth
1997 0
1998 35.564 100%
1999 29.804 -19.33%
2000 23.703 -25.74%
2001 17.294 -37.06%
2002 11.769 -46.95%
2003 5.876 -100.29%
2004 1.078 -445.08%
2005 12.523 91.39%
2006 6.842 -83.03%
2007 12.527 45.38%
2008 1.818 -589.05%
2009 3.257 44.18%
2010 4.463 27.02%
2011 6.989 36.14%
2012 4.505 -55.14%
2013 359 -1154.87%
2014 19.134 98.12%
2015 74.653 74.37%
2016 67.269 -10.98%
2017 4.807 -1299.4%
2018 32.495 85.21%
2019 9.273 -250.43%
2020 893 -938.41%
2021 734 -21.66%
2022 295 -148.81%
2023 483 38.92%
2023 138 -250%
2024 10.168 98.64%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bioethics, Ltd. Liabilities
Year Liabilities Growth
1997 0
1998 899 100%
1999 670 -34.18%
2000 650 -3.08%
2001 1.184 45.1%
2002 740 -60%
2003 740 0%
2004 1.800 58.89%
2005 40 -4400%
2006 0 0%
2007 1.706 100%
2008 2.820 39.5%
2009 8.424 66.52%
2010 26.430 68.13%
2011 53.730 50.81%
2012 77.291 30.48%
2013 95.672 19.21%
2014 25.000 -282.69%
2015 76.087 67.14%
2016 187.331 59.38%
2017 189.092 0.93%
2018 300.320 37.04%
2019 375.012 19.92%
2020 479.623 21.81%
2021 586.647 18.24%
2022 679.411 13.65%
2023 752.345 9.69%
2023 776.403 3.1%
2024 862.018 9.93%

Bioethics, Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.11
Price to Earning Ratio
-19.03x
Price To Sales Ratio
0x
POCF Ratio
-47.68
PFCF Ratio
-47.68
Price to Book Ratio
-2.73
EV to Sales
0
EV Over EBITDA
-38.06
EV to Operating CashFlow
-57.55
EV to FreeCashFlow
-57.55
Earnings Yield
-0.05
FreeCashFlow Yield
-0.02
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.35
Graham NetNet
-0.75

Income Statement Metrics

Net Income per Share
-0.11
Income Quality
0.4
ROE
0.15
Return On Assets
-12.03
Return On Capital Employed
0.09
Net Income per EBT
1
EBT Per Ebit
1.66
Ebit per Revenue
0
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.16
Return on Tangible Assets
-12.03
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,75
Tangible Book Value per Share
-0.75
Shareholders Equity per Share
-0.75
Interest Debt per Share
0.48
Debt to Equity
-0.58
Debt to Assets
48.36
Net Debt to EBITDA
-6.52
Current Ratio
0.01
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-851850
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.21

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bioethics, Ltd. Dividends
Year Dividends Growth

Bioethics, Ltd. Profile

About Bioethics, Ltd.

Bioethics, Ltd. does not have significant operations. It intends to seek, investigate, and if warranted acquire an interest in a business opportunity. The company was incorporated in 1990 and is based in Ogden, Utah.

CEO
Mr. Mark A. Scharmann
Employee
0
Address
1661 Lakeview Circle
Ogden, 84403

Bioethics, Ltd. Executives & BODs

Bioethics, Ltd. Executives & BODs
# Name Age
1 Mr. Mark A. Scharmann
President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer & Director
70
2 Mr. Douglas P. Morris
Vice President of Corporate Development & Director
70

Bioethics, Ltd. Competitors